SCHEMBL416422

SCHEMBL416422

O=C1CCC(OCc2ccccc2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 2/20 0.50
OPRL1 P41146 2/20 0.50
DPP4 P27487 1/20 0.50
SIGMAR1 Q99720 2/20 0.48
PSEN1 P49768 4/20 0.48
PSEN2 P49810 4/20 0.48
APH1B Q8WW43 4/20 0.48
NCSTN Q92542 4/20 0.48
APH1A Q96BI3 4/20 0.48
PSENEN Q9NZ42 4/20 0.48
TMEM97 Q5BJF2 1/20 0.48
CARM1 Q86X55 1/20 0.48
PRMT6 Q96LA8 1/20 0.48
PRMT8 Q9NR22 1/20 0.48
HRH3 Q9Y5N1 1/20 0.48
CTSL P07711 2/20 0.47
CTSB P07858 2/20 0.47
CTSK P43235 2/20 0.47
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ethylene SCHEMBL7936439 0.96 OPRM1 (0.48) OPRM1OPRL1DPP4SIGMAR1PSEN1
SCHEMBL420469 0.93 PSEN1 (0.50) OPRM1OPRL1DPP4SIGMAR1PSEN1
SCHEMBL7753890 0.91 ESR2 (0.47) OPRM1OPRL1DPP4SIGMAR1PSEN1
SCHEMBL1288390 0.89 CYP3A4 (0.47) OPRM1OPRL1DPP4SIGMAR1PSEN1
SCHEMBL7985833 0.89 CYP3A4 (0.47) OPRM1OPRL1DPP4SIGMAR1PSEN1
Hydantoin SCHEMBL7934632 0.84 OPRM1 (0.45) OPRM1OPRL1DPP4SIGMAR1PSEN1
SCHEMBL6469380 0.84 OPRM1 (0.59) OPRM1OPRL1DPP4SIGMAR1TMEM97
Hydrochloric Acid SCHEMBL5722088 0.83 DPP4 (0.56) OPRM1OPRL1DPP4SIGMAR1PSEN1
SCHEMBL418931 0.82 SIGMAR1 (0.41) OPRM1OPRL1DPP4SIGMAR1PSEN1
SCHEMBL7461849 0.82 CYP3A4 (0.40) OPRM1OPRL1DPP4PSEN1PSEN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 358 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260068886-A1 COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL OERTH BIO LLC (US) 2026-03-12 US disclosed
EP-3924058-B1 5-ALKYL PYRROLIDINE OREXIN RECEPTOR AGONISTS MERCK SHARP & DOHME LLC (US) 2026-01-07 EP disclosed
US-12486253-B2 Therapeutics for the degradation of mutant BRAF C4 THERAPEUTICS, INC. (US) 2025-12-02 US disclosed
EP-4626423-A1 CDK INHIBITORS AND METHODS AND USE THEREOF Relay Therapeutics, Inc. (US) 2025-10-08 EP disclosed
EP-3782994-B1 COMPOUNDS USEFUL AS KINASE INHIBITORS LOXO ONCOLOGY INC (US) 2025-07-16 EP disclosed
EP-4580405-A1 COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL Oerth Bio LLC (US) 2025-07-09 EP disclosed
WO-2025120200-A1 NEW ANTI-INFECTIVE TRICYCLIC SPIROLACTAMS COMPOUNDS INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) 2025-06-12 WO disclosed
EP-4558137-A2 CHROMANE AMIDINE MONOBACTAM COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS Merck Sharp & Dohme LLC (US) 2025-05-28 EP disclosed
WO-2025096858-A1 COMPOUNDS FOR THE DEGRADATION OF MUTANT BRAF C4 THERAPEUTICS, INC. (US) 2025-05-08 WO disclosed
US-20250115580-A1 THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF C4 THERAPEUTICS, INC. (US) 2025-04-10 US disclosed
US-5175319-A Antiprotozoa agent, useful for treating malaria, theileriosis, coccidiosis and prophylaxix BURROUGHS WELLCOME CO. (US) 1992-12-29 US disclosed
US-5053432-A Antiprotozoa agents; treatment of malaria BURROUGHS WELLCOME CO. (US) 1991-10-01 US disclosed
EP-0369388-A1 Hydroxy-1,2,3,4-tetrahydroaminoacridines, a process for their preparation and their use as medicaments HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1990-05-23 EP disclosed
US-4721725-A Aryl-cycloalkyl[b]pyrrole derivatives E. R. SQUIBB & SONS, INC. (US) 1988-01-26 US disclosed
EP-0123238-A2 Naphthoquinone derivatives THE WELLCOME FOUNDATION LIMITED (GB) 1984-10-31 EP disclosed
US-4257952-A PSYCHOTROPIC DRUGS, ANALGESICS, ANTIHISTAMINES STERLING DRUG INC. (US) 1981-03-24 US disclosed
US-4172834-A ANALGESICS, ANTIHISTAMINES AND PSYCHOTROPIC AGENTS STERLING DRUG INC. (US) 1979-10-30 US disclosed
US-4062864-A ANALGESIC, PSYCHOTROPIC, ANTIHISTAMINE STERLING DRUG INC. (US) 1977-12-13 US disclosed
US-3968121-A 1,2-Diphenyl-4,5,6,7-tetrahydroindoles STERLING DRUG INC. (US) 1976-07-06 US disclosed
US-3959309-A ANALGESICS, PSYCHOTROPIC, ANTIHISTAMINE STERLING DRUG INC. (US) 1976-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12486253-B2 Therapeutics for the degradation of mutant BRAF BRAF, NRAS, KRAS OPRM1 4480/4885OPRL1 4108/4885DPP4 3106/4885
US-20250115580-A1 THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF BRAF, NRAS, KRAS OPRM1 4480/4885OPRL1 4108/4885DPP4 3106/4885
US-20260068886-A1 COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL CRBN, STUB1, CUL1 OPRM1 2866/4885OPRL1 3838/4885DPP4 4366/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.